FDA approves first treatment for all HCV genotypes in CHILDREN (USA)

This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.

FDA approves MAVYRET™, the first treatment for all genotypes of hepatitis C approved by this US agency for pediatric use. On behalf of Canada’s children, we hope Canada will soon follow (Canada’s version of AbbVie’s hepatitis C drug is spelled Maviret™)!

For Immediate Release, April 30, 2019

https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-all-genotypes-hepatitis-c-pediatric-patients